liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Safety and immunogenicity, after nasal application of HIV-1 DNA gagp37 plasmid vaccine in young mice
Linköping University, Faculty of Health Sciences. Linköping University, Department of Clinical and Experimental Medicine, Molecular Virology .
Linköping University, Faculty of Health Sciences. Linköping University, Department of Clinical and Experimental Medicine, Molecular Virology .
Swedish Institute for Infectious Disease Control Microbiology and Tumorbiology Center Karolinska Institute, Solna.
Eurocine AB Karolinska Science Park, Stockholm.
2008 (English)In: Vaccine, ISSN 0264-410X, Vol. 26, no 40, 5101-5106 p.Article in journal (Refereed) Published
Abstract [en]

Background: There is a need for safe and potent adjuvants capable of delivering vaccine candidates over the mucosal barrier, with good capacity to stimulate both mucosal and systemic cell-mediated and humoral immunity. An adjuvant aimed for intranasal delivery should preferably deliver the antigen and minimize the transfer into the close proximity of the central nervous system, thus avoiding damage on the olfactory tissues. Advantages with a mucosal delivery route would be to provide mucosal and systemic immunity, requiring lower vaccine doses then when given parentally. The aim of this study was to study if the N3 adjuvant intranasally administered with HIV DNA plasmids would be transferred into the olfactory tissues and cause local inflammation and tissue damage. Results: The N3 adjuvant alone and when combined with HIV-1 DNA gag plasmid and delivered intranasally did not cause detectable damage to the nasal epithelium or the olfactory epithelium or bulb over a period of 3 days after delivery. The intranasal administration of HIV-1 gagp37 DNA induced both a humoral and a cell-mediated immunity against the gag antigen. Significantly higher HIV-1-specific humoral, but not cell-mediated immune responses were seen in DNA/N3-immunized mice in comparison with HIV-1 DNA/saline-immunized animals. Conclusions: A safe and convenient intranasal mode of HIV-1 DNA plasmid and adjuvant delivery was shown not to interfere with the tissues in close proximity to the central nervous system. The N3 adjuvant combined with HIV-1 plasmids enhances the HIV-1-specific immunogenicity and merits to be clinically tested. © 2008 Elsevier Ltd. All rights reserved.

Place, publisher, year, edition, pages
2008. Vol. 26, no 40, 5101-5106 p.
National Category
Medical and Health Sciences
URN: urn:nbn:se:liu:diva-43345DOI: 10.1016/j.vaccine.2008.03.098Local ID: 73590OAI: diva2:264204
Available from: 2009-10-10 Created: 2009-10-10 Last updated: 2011-01-10

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Hinkula, JormaHagbom, Marie
By organisation
Faculty of Health SciencesMolecular Virology
In the same journal
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 42 hits
ReferencesLink to record
Permanent link

Direct link